Zai Lab of Shanghai is conducting a Hong Kong IPO that is expected to raise $845 million, based on the price of the company's US-listed shares. On the NASDAQ Exchange, Zai has a market capitalization of $6.2 billion. The company is developing a large portfolio of in-licensed cancer and infectious disease candidates. Its PARP inhibitor is approved for China use in ovarian cancer and a medical device, Tumor Treating Fields, is approved in China for glioblastoma. More details.... Stock Symbol: (NSDQ: ZLAB) Share this with colleagues: // //